Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

See full Press Release by clicking the link below!

DBM PR 5 July 2022

.pdf

Download PDF • 401KB

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist

AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Sage Group is attending BIO 2023 in Boston from 5-8 June 2023! Please click here to setup a call with us in advance or book on the partnering sessions!